Objectives
This Nurse Learning Module will provide an overview of the current management of diffuse large B-cell lymphoma in Australia and internationally. The module will aim to be an interactive webinar that will include case studies to enhance your learning.
The presentation will include how diffuse large B-cell lymphoma is diagnosed, staged, prognostic indicators, current treatments in first-line management, the relapsed/refractory setting for patients and emerging therapies.
At the completion of module five, participants will have an in-depth knowledge of some of the new therapies available for B-cell lymphoma patients. Participants will understand:
- Pathophysiology of diffuse large B-cell lymphoma
- The different subtypes of diffuse large B-cell lymphoma
- How and why treatment decisions are made for patients
- The different treatments available for diffuse large B-cell lymphoma patients
- Management of patients in the relapsed or refractory setting
Module five presentations
Diffuse large B-cell lymphoma
Professor Mark Hertzberg – Director, Department of Haematology, Prince of Wales Hospital, Sydney, NSW
Professor Hertzberg is the Director of the Clinical Haematology Service at the Prince of Wales Hospital and University of NSW in Sydney.Â
He has a particular interest in clinical trials with expertise in the area of Lymphoma.Â
He is a Past President of the Haematology Society Australia and New Zealand, and for 7 years was the Chair of the Scientific Advisory Committee of the Australasian Leukaemia Lymphoma Group.
He serves on the Scientific Advisory Committee of the 12th International Hodgkin Lymphoma Symposium.
Post assessment & Evaluation Survey​
To be eligible for a certificate of attendance, you need to complete a short assessment. The certificate will be emailed to you shortly after you have submitted the assessment.
Further reading and resources
Coiffier, B., C. Thieblemont, E. Van Den Neste, et al. 2010. “Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte.” Blood 116(12):2040-2045
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951853/
Coiffier, B., E. Lepage, J. Briere, et al. 2002. “CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.” N.Engl.J.Med. 346(4):235-242.
https://www.nejm.org/doi/full/10.1056/nejmoa011795
Fisher, R. I., E. R. Gaynor, S. Dahlberg, et al. 1993. “Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma.” N.Engl.J.Med. 328(14):1002-1006.
https://www.nejm.org/doi/full/10.1056/nejm199304083281404
Gottlieb JA, Gutterman JU, McCredie KB, et al. 1973. “Chemotherapy of malignant lymphoma with adriamycin.” Cancer Res. 33(11):3024-3028
https://cancerres.aacrjournals.org/content/canres/33/11/3024.full.pdf
Armatage, James, How I treat patients with diffuse large B-cell lymphoma, Blood Journal, 2007
https://ashpublications.org/blood/article/110/1/29/133610/How-I-treat-patients-with-diffuse-large-B-cell
Sesques, Pierre, Johnson, Nathalie, Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements, Blood journal, 2017
https://ashpublications.org/blood/article/129/3/280/36006/Approach-to-the-diagnosis-and-treatment-of-high
